Bristol-Myers Squibb Co.’s cancer drug Opdivo has scored another FDA nod – this time in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This is the seventh approval for Opdivo in just over a year, and the fourth for late-stage melanoma.